The cytotoxicity of a recombinant adenovirus expressing the wild type tumor suppressor
gene p53 (AdWTp53) was studied in two human breast cancer MCF-7 sublines selected for …

In this study we characterize the connections between p53-dependent G1 cell cycle arrest,
transcriptional activation of the protein and the increase of its intracellular steady-state …

In the present study, we report the characterization of the p53 tumor suppressor pathway in
the 60 cell lines of the National Cancer Institute (NCI) anticancer drug screen, as well as …

In contrast to findings in vitro, the clinical response to anticancer chemotherapy is not simply
associated with the p53 mutation status. To analyze the relationship between the actual …

The present study was performed to gain insight into the role of p53 on the cytotoxicity of
tubulin-binding agents (TBA) on cancer cells. Drug sensitivity, cell cycle distribution and …

Mutations of the tumor suppressor wild-type p53 gene have been implicated in the
development of resistance to anticancer drugs. We have examined the role of wild-type p53 …

The activation of p53 has been proposed as a novel anti-cancer treatment in two distinct
contexts. In the first activation of p53 in tumor cells can promote apoptosis and senescence …

Many tumor types have p53 and/or RB mutations, and it is unclear what role the mutations of
these tumor suppressor genes have on the efficacy of chemotherapeutic agents. The effect …

We evaluated cell survival, DNA double strand breaks (dsbs), and DNA synthesis following
camptothecin (CPT) alone or concurrent CPT and X‐radiation treatments in exponential …

We have analysed the cell-cycle arrests and cytotoxicity of the A2780 human ovarian cell
line in response to geldanamycin, a benzoquinoid ansamycin that can inhibit tyrosine …